CervoMed的痴呆药物试验失败了 导致库存暴跌 尽管安全情况良好 CervoMed's dementia drug trial fails, causing stock to plummet despite good safety profile.

CervoMed的药物候选者Neplamapimod在对Lewy尸体进行痴呆的中阶段试验中未能实现其目标,导致公司股票大幅下降。 CervoMed's drug candidate, neflamapimod, failed to meet its goals in a mid-stage trial for dementia with Lewy bodies, leading to a significant drop in the company's stock. 尽管药物表现出良好的安全性,但它没有降低痴呆症的严重程度,也没有达到次要目标。 Despite the drug showing good safety, it did not reduce dementia severity or meet secondary goals. 该公司将调查为何药物水平低于预期水平,预计2025年1月将获得审判的全部数据。 The company will investigate why the drug levels were lower than expected, and full data from the trial is expected in January 2025.